The Expression Patterns of Antibody–Drug Conjugate-Related Markers in Urothelial Carcinoma With Histological Variants

Xingliang Tan; Xinpei Deng; KunYang Wang; Zhiming Wu; Yanjun Wang; Chichen Zhang; Qianghua Zhou; Yun Cao; Neng Jiang; Kai Yao

doi:10.1002/mco2.70865

MedComm ›› 2026, Vol. 7 ›› Issue (8) :e70865 DOI: 10.1002/mco2.70865

LETTER

The Expression Patterns of Antibody–Drug Conjugate-Related Markers in Urothelial Carcinoma With Histological Variants

Xingliang Tan ¹^,²
, Xinpei Deng ¹^,²
, KunYang Wang ¹^,²
, Zhiming Wu ¹^,²
, Yanjun Wang ¹^,²
, Chichen Zhang ¹^,²
, Qianghua Zhou ¹^,²
, Yun Cao ¹^,²
, Neng Jiang ¹^,²
, Kai Yao ¹^,²

Author information +

History +

PDF (233KB)

Cite this article

Download citation ▾

Xingliang Tan, Xinpei Deng, KunYang Wang, Zhiming Wu, Yanjun Wang, Chichen Zhang, Qianghua Zhou, Yun Cao, Neng Jiang, Kai Yao. The Expression Patterns of Antibody–Drug Conjugate-Related Markers in Urothelial Carcinoma With Histological Variants. MedComm, 2026, 7 (8) : e70865 DOI:10.1002/mco2.70865

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	R. L. Siegel, T. B. Kratzer, A. N. Giaquinto, H. Sung, and A. Jemal, “Cancer Statistics, 2025,” CA: A Cancer Journal for Clinicians 75, no. 1 (2025): 10–45.

[2]	T. Powles, B. P. Valderrama, S. Gupta, et al., “Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer,” New England Journal of Medicine 390, no. 10 (2024): 875–888.

[3]	X. Sheng, G. Zeng, C. Zhang, et al., “Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer,” New England Journal of Medicine 393, no. 23 (2025): 2324–2337.

[4]	X. Bian, T. Yang, H. Yin, et al., “Efficacy and Safety of BL-B01D1 in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial,” Journal of Clinical Oncology 43, no. 32 (2025): 3505–3515.

[5]	M. Kossaï, C. Radulescu, J. Adam, et al., “Plasmacytoid Urothelial Carcinoma (UC) Are Luminal Tumors With Similar CD8+ Tcell Density and PD-L1 Protein Expression on Immune Cells as Compared to Conventional UC,” Urologic Oncology 40, no. 1 (2022): 12. e11.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.